Immunotherapy and tumor microenvironment

Cancer Letters

Volumn 370, Issue 1, 2016, Pages 85-90

  Tang, Haidong ^a   Qiao, Jian ^a   Fu, Yang Xin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

CAR T cell therapy; Checkpoint blockade; Chemokine; Cytokine; Tumor microenvironment; Tumor infiltrating immune cells

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE; CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON INDUCIBLE PROTEIN 10; PATTERN RECOGNITION RECEPTOR; PATTERN RECOGNITION RECEPTOR AGONIST; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; SECONDARY LYMPHOID TISSUE CHEMOKINE; UNCLASSIFIED DRUG; CCL21 PROTEIN, HUMAN; CD274 PROTEIN, HUMAN; HERPESVIRUS ENTRY MEDIATOR LIGAND; LYMPHOCYTE ANTIGEN RECEPTOR; TNFSF14 PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG RESEARCH; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; MACROPHAGE ACTIVATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PHYSIOLOGY; T LYMPHOCYTE;

ANTIGENS, CD274; CHEMOKINE CCL21; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, PATTERN RECOGNITION; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14;

EID: 84949454830     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.10.009     Document Type: Review

References (89)

1. Couzin-Frankel J. Cancer immunotherapy. Science 2013, 342(6165):1432-1433.
2. Porter D.L., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. NEJM 2011, 365(8):725-733.
3. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. NEJM 2012, 366(26):2443-2454.
4. Brahmer J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. NEJM 2012, 366(26):2455-2465.
5. Holohan C., et al. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 2013, 13(10):714-726.
6. Shin D.S., Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. Curr. Opin. Immunol 2015, 33:23-35.
7. Boon T., van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med 1996, 183(3):725-729.
8. Rosenberg S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999, 10(3):281-287.
9. Zinkernagel R.M. Immunity against solid tumors?. Int. J. Cancer 2001, 93(1):1-5.
10. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 2001, 411(6835):380-384.
11. Yu P., Fu Y.-X. Tumor-infiltrating T lymphocytes: friends or foes?. Lab. Invest 2006, 86(3):231-245.
12. Klemm F., Joyce J.A. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol 2015, 25(4):198-213.
13. Devaud C., et al. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2013, 2(8):e25961.
14. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12(4):252-264.
15. Nishimura H., et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001, 291(5502):319-322.
16. Keir M.E., et al. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol 2008, 26:677-704.
17. Dong H., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med 2002, 8(8):793-800.
18. Iwai Y., et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. PNAS 2002, 99(19):12293-12297.
19. Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol 2012, 24(2):207-212.
20. Blank C., et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004, 64(3):1140-1145.
21. Crespo J., et al. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr. Opin. Immunol 2013, 25(2):214-221.
22. Taube J.M., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res 2014, 20(19):5064-5074.
23. Herbst R.S., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515(7528):563-567.
24. Ai M., Curran M.A. Immune checkpoint combinations from mouse to man. Cancer Immunol. Immunother 2015, 64(7):885-892.
25. Wolchok J.D., et al. Nivolumab plus ipilimumab in advanced melanoma. NEJM 2013, 369(2):122-133.
26. Hammers H.J., et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) 2014, In ASCO Annual Meeting Proceedings.
27. Postow M.A., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. NEJM 2015, 372(21):2006-2017.
28. Cha E., et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci. Transl. Med 2014, 6(238):238ra70.
29. Spranger S., et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8 (+) T cells directly within the tumor microenvironment. J. Immunother. Cancer 2014, 2:3.
30. Melero I., et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 2007, 7(2):95-106.
31. Armitage R.J., et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992, 357(6373):80-82.
32. Vonderheide R.H. Prospect of targeting the CD40 pathway for cancer therapy. Clin. Cancer Res 2007, 13(4):1083-1088.
33. Schoenberger S.P., et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393(6684):480-483.
34. Bennett S.R., et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998, 393(6684):478-480.
35. +; T-helper and a T-killer cell. Nature 1998, 393(6684):474-478.
36. French R.R., et al. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med 1999, 5(5):548-553.
37. Diehl L., et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med 1999, 5(7):774-779.
38. Sotomayor E.M., et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med 1999, 5(7):780-787.
39. Beatty G.L., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331(6024):1612-1616.
40. Vonderheide R.H., Glennie M.J. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res 2013, 19(5):1035-1043.
41. Bouchlaka M.N., et al. Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J. Exp. Med 2013, 210(11):2223-2237.
42. Mirsoian A., et al. Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. J. Exp. Med 2014, 211(12):2373-2383.
43. Merghoub T., Wolchok J.D. Immunotherapy and the belly of the beast. J. Exp. Med 2014, 211(12):2327-2328.
44. Srivastava S., Riddell S.R. Engineering CAR-T cells: design concepts. Trends Immunol 2015, 36(8):494-502.
45. Maher J., et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat. Biotechnol 2002, 20(1):70-75.
46. Grupp S.A., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. NEJM 2013, 368(16):1509-1518.
47. Davila M.L., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med 2014, 6(224):224ra25.
48. Kershaw M.H., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res 2006, 12(20):6106-6115.
49. Pule M.A., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med 2008, 14(11):1264-1270.
50. Adusumilli P.S., et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med 2014, 6(261):261ra151.
51. Bernfield M., et al. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem 1999, 68(1):729-777.
52. Caruana I., et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat. Med 2015, 21(5):524-529.
53. Vlodavsky I., et al. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr. Pharm. Des 2007, 13(20):2057-2073.
54. Griffith J.W., Sokol C.L., Luster A.D. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu. Rev. Immunol 2014, 32:659-702.
55. Chow M.T., Luster A.D. Chemokines in cancer. Cancer Immunol. Res 2014, 2(12):1125-1131.
56. Homey B., Müller A., Zlotnik A. Chemokines: agents for the immunotherapy of cancer?. Nat. Rev. Immunol 2002, 2(3):175-184.
57. Bromley S.K., Mempel T.R., Luster A.D. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat. Immunol 2008, 9(9):970-980.
58. Lo J.C., et al. Differential regulation of CCL21 in lymphoid/nonlymphoid tissues for effectively attracting T cells to peripheral tissues. J. Clin. Invest 2003, 112(10):1495-1505.
59. Sharma S., et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol 2000, 164(9):4558-4563.
60. Yang S.-C., et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin. Cancer Res 2004, 10(8):2891-2901.
61. Shields J.D., et al. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 2010, 328(5979):749-752.
62. Farber J.M. Mig and IP-10: CXC chemokines that target lymphocytes. J. Leukoc. Biol 1997, 61(3):246-257.
63. da Silva R.B., et al. Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat. Immunol 2015, 16(8):850-858.
64. Lee S., Margolin K. Cytokines in cancer immunotherapy. Cancers 2011, 3(4):3856-3893.
65. Johansson A., Hamzah J., Ganss R. License for destruction: tumor-specific cytokine targeting. Trends Mol. Med 2014, 20(1):16-24.
66. Smyth M.J., et al. Cytokines in cancer immunity and immunotherapy. Immunol. Rev 2004, 202(1):275-293.
67. Xuan C., et al. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood 2010, 115(14):2864-2871.
68. Yang X., et al. Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell 2014, 25(1):37-48.
69. Spaapen R.M., et al. Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature. J. Immunol 2014, 193(8):4254-4260.
70. Woo S.-R., Corrales L., Gajewski T.F. Innate immune recognition of cancer. Annu. Rev. Immunol 2015, 33:445-474.
71. Galon J., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964.
72. Mahmoud S.M., et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol 2011, 29(15):1949-1955.
73. Hwang W.-T., et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol. Oncol 2012, 124(2):192-198.
74. Wang Y., et al. Immunoregulation by tumor necrosis factor superfamily member LIGHT. Immunol. Rev 2009, 229(1):232-243.
75. Yu P., et al. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J. Immunol 2007, 179(3):1960-1968.
76. Yu P., et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol 2004, 5(2):141-149.
77. Fu Y.-X., Chaplin D.D. Development and maturation of secondary lymphoid tissues. Annu. Rev. Immunol 1999, 17(1):399-433.
78. Ware C.F. Network communications: lymphotoxins, LIGHT, and TNF. Annu. Rev. Immunol 2005, 23:787-819.
79. Cyster J.G. Chemokines and cell migration in secondary lymphoid organs. Science 1999, 286(5447):2098-2102.
80. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 2004, 4(1):11-22.
81. Broz P., Monack D.M. Newly described pattern recognition receptors team up against intracellular pathogens. Nat. Rev. Immunol 2013, 13(8):551-565.
82. Honda K., et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434(7034):772-777.
83. Hoffman E.S., Smith R.E., Renaud R.C. TLR-targeted therapeutics. Nat. Rev. Drug Discov 2005, 4(11):879-880.
84. Krieg A.M. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther 2012, 22(2):77-89.
85. Sharma S., et al. Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice. Cancer Res 2008, 68(18):7530-7540.
86. Schettini J., et al. Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity. Cancer Immunol. Immunother 2012, 61(11):2055-2065.
87. Jahrsdörfer B., Weiner G.J. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther 2008, 3(1):27-32.
88. Woo S.-R., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014, 41(5):830-842.
89. Deng L., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014, 41(5):843-852.